Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis

Biochemical and Biophysical Research Communications

Volumn 445, Issue 2, 2014, Pages 375-380

  Xing, S S ^a   Shen, C C ^a   Godard, M P ^b   Wang, J J ^a   Yue, Y Y ^a   Yang, S T ^a   Zhao, Q ^a   Zhang, S B ^a   Wang, T X ^a   Yang, X L ^a   Delafontaine, P ^c   He, Y ^d   Song, Y H ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF CENTRAL MISSOURI   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Bortezomib; C2C12; Differentiation

Indexed keywords

BORTEZOMIB; CASPASE 3; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MYOGENIN; PROPIDIUM IODIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; INTRACELLULAR SIGNALING; MOUSE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANIMALIA;

BORTEZOMIB; C2C12; DIFFERENTIATION;

ANIMALS; APOPTOSIS; BORONIC ACIDS; CELL LINE; CELL SURVIVAL; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G2 PHASE CELL CYCLE CHECKPOINTS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MUSCLE FIBERS, SKELETAL; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84896076251     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.02.008     Document Type: Article

References (27)

1. D. Chauhan, G. Bianchi, and K.C. Anderson Targeting the UPS as therapy in multiple myeloma BMC Biochem. 9 Suppl. 1 2008 S1
2. J. Adams, M. Behnke, S. Chen, A.A. Cruickshank, L.R. Dick, L. Grenier, J.M. Klunder, Y.T. Ma, L. Plamondon, and R.L. Stein Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids Bioorg. Med. Chem. Lett. 8 1998 333 338 (Pubitemid 28072702)
3. A.F. Kisselev, and A.L. Goldberg Proteasome inhibitors: from research tools to drug candidates Chem. Biol. 8 2001 739 758 (Pubitemid 32752454)
4. G. Nalepa, M. Rolfe, and J.W. Harper Drug discovery in the ubiquitin-proteasome system Nat. Rev. Drug Discov. 5 2006 596 613
5. P.J. Elliott, and J.S. Ross The proteasome: a new target for novel drug therapies Am. J. Clin. Pathol. 116 2001 637 646 (Pubitemid 34453203)
6. R. Schwartz, and T. Davidson Pharmacology, pharmacokinetics, and practical applications of bortezomib Oncology (Williston Park) 18 2004 14 21
7. J.F. San-Miguel, P.G. Richardson, A. Gunther, O. Sezer, D. Siegel, J. Blade, R. Leblanc, H. Sutherland, M. Sopala, K.K. Mishra, S. Mu, P.M. Bourquelot, M. Victoria Mateos, and K.C. Anderson Phase ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma J. Clin. Oncol. 31 2013 3696 3703
8. R.I. Fisher, S.H. Bernstein, B.S. Kahl, B. Djulbegovic, M.J. Robertson, S. de Vos, E. Epner, A. Krishnan, J.P. Leonard, S. Lonial, E.A. Stadtmauer, O.A. O'Connor, H. Shi, A.L. Boral, and A. Goy Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J. Clin. Oncol. 24 2006 4867 4874 (Pubitemid 46655613)
9. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, D. Siegel, R.Z. Orlowski, D. Kuter, S.A. Limentani, S. Lee, T. Hideshima, D.L. Esseltine, M. Kauffman, J. Adams, D.P. Schenkein, and K.C. Anderson A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 348 2003 2609 2617 (Pubitemid 36741588)
10. A. Agten, K. Maes, D. Thomas, N. Cielen, H.W. Van Hees, R.P. Dekhuijzen, M. Decramer, and G. Gayan-Ramirez Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction Crit. Care Med. 40 2012 2449 2455
11. H.H. Bach 4th, H.M. Laporte, Y.M. Wong, R.L. Gamelli, and M. Majetschak Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats J. Trauma Acute Care Surg. 74 2013 499 507
12. S. Rayavarapu, W. Coley, J.H. Van der Meulen, E. Cakir, K. Tappeta, T.B. Kinder, B.C. Dillingham, K.J. Brown, Y. Hathout, and K. Nagaraju Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target Arthritis Rheum. 65 2013 3248 3258
13. C. Madeddu, and G. Mantovani An update on promising agents for the treatment of cancer cachexia Curr. Opin. Support Palliat. Care 3 2009 258 262
14. B.C. Beehler, P.G. Sleph, L. Benmassaoud, and G.J. Grover Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation Exp. Biol. Med. (Maywood) 231 2006 335 341 (Pubitemid 43334321)
15. H. van Hees, C. Ottenheijm, L. Ennen, M. Linkels, R. Dekhuijzen, and L. Heunks Proteasome inhibition improves diaphragm function in an animal model for COPD Am. J. Physiol. Lung Cell Mol. Physiol. 301 2011 L110 L116
16. C.H. Lang, D. Huber, and R.A. Frost Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 2007 R328 R336
17. J. Voortman, and G. Giaccone Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report BMC Cancer 6 2006 129
18. A. Hacihanefioglu, P. Tarkun, and E. Gonullu Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib Int. J. Hematol. 88 2008 219 222
19. D. Nowis, M. Maczewski, U. Mackiewicz, M. Kujawa, A. Ratajska, M.R. Wieckowski, G.M. Wilczynski, M. Malinowska, J. Bil, P. Salwa, M. Bugajski, C. Wojcik, M. Sinski, P. Abramczyk, M. Winiarska, A. Dabrowska-Iwanicka, J. Duszynski, M. Jakobisiak, and J. Golab Cardiotoxicity of the anticancer therapeutic agent bortezomib Am. J. Pathol. 176 2010 2658 2668
20. I. Saeki, S. Terai, K. Fujisawa, T. Takami, N. Yamamoto, T. Matsumoto, Y. Hirose, Y. Murata, T. Yamasaki, and I. Sakaida Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis J. Gastroenterol. 48 2013 738 750
21. A.C. Ronda, A. Vasconsuelo, and R. Boland 17Beta-estradiol protects mitochondrial functions through extracellular-signal-regulated kinase in C2C12 muscle cells Cell Physiol. Biochem. 32 2013 1011 1023
22. B.J. Krawiec, R.A. Frost, T.C. Vary, L.S. Jefferson, and C.H. Lang Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis Am. J. Physiol. Endocrinol. Metab. 289 2005 E969 E980
23. G.S. Supinski, J. Vanags, and L.A. Callahan Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction Am. J. Physiol. Lung Cell Mol. Physiol. 296 2009 L994 L1001
24. M.U. Fareed, A.R. Evenson, W. Wei, M. Menconi, V. Poylin, V. Petkova, B. Pignol, and P.O. Hasselgren Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression Am. J. Physiol. Regul. Integr. Comp. Physiol. 290 2006 R1589 R1597
25. G.S. Supinski, and L.A. Callahan Caspase activation contributes to endotoxin-induced diaphragm weakness J. Appl. Physiol. 100 2006 1770 1777 (Pubitemid 43845849)
26. E.E. Talbert, A.J. Smuder, K. Min, O.S. Kwon, and S.K. Powers Calpain and caspase-3 play required roles in immobilization-induced limb muscle atrophy J. Appl. Physiol. (1985) 114 2013 1482 1489
27. H.C. Drexler, W. Risau, and M.A. Konerding Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells FASEB J. 14 2000 65 77 (Pubitemid 30051524)